Abstract
Cushing’s disease, i.e., pituitary ACTH-secreting adenoma causing excess glucocorticoid secretion, is a rare disease with significant mortality and morbidity. Timely diagnosis and appropriate treatment can alter the course of the disease and are therefore mandatory. First step of the diagnostic work-up is the endogenous glucocorticoid excess by measurement of urinary free cortisol, cortisol circadian rhythmicity or suppression by low doses of dexamethasone. In patients with equivocal results, second line tests, such as the dexamethasone-suppressed CRH test and desmopressin stimulation, usually enable the diagnosis to be confirmed. Measurement of plasma ACTH then allows the distinction between ACTH-dependent (e.g., pituitary or extrapituitary neuroendocrine tumors) and ACTH-independent causes (e.g., adrenal tumors). The last step in the diagnostic algorhythm is often the most fraught with problems as the distinction between Cushing’s disease and ectopic ACTH secretion relies on judicious interpretation of several diagnostic procedures. Positive responses to stimulation with CRH and inhibition by high doses of dexamethasone, if concurrent, enable a pituitary origin to be established whereas conflicting results call for inferior petrosal sinus sampling, the latter to be performed in experienced centres only. Visualisation of the tumor at pituitary imaging is helpful but not required for the diagnosis, as microadenomas often remain undectected by MRI and/or CT scan and, on the other hand, visualisation of a non-secreting incidentaloma may be misleading. Surgical removal of the pituitary tumor is the optimal treatment choice and should be attempted in every patient. Surgical failures as well as relapses can be treated by radiotherapy, medical therapy or, if necessary, bilateral adrenalectomy. Finally, patients cured of Cushing’s disease require long-term monitoring given the risk of relapse and clinical burden of associated ailments.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Etxabe J, Vazquez JA (1994) Morbidity and mortality in Cushing’s disease: an epidemiological approach. Clin Endocrinol 40:479–484
Savage MO, Besser GM (1996) Cushing’s disease in childhood. Trends Endocrinol Metab 7:213–216
Brandi ML, Marx SJ, Aurbach GD, Fitzpatrick LA (1987) Familial multiple endocrine neoplasia type I: a new look at pathophysiology. Endocr Rev 8:391–405
Lionakis MS, Kontoyiannis DP (2003) Glucocorticoids and invasive fungal infections. Lancet 362:1828–1838
Plotz CM, Knowlton AI, Ragan C (1952) The natural history of Cushing’s syndrome. Am J Med 13:597–614
Perry LA, Grossman AB (1997) The role of the laboratory in the diagnosis of Cushing’s syndrome. Ann Clin Biochem 34:345–359
Burke CW, Beardwell CG (1973) Cushing’s syndrome. An evaluation of the clinical usefulness of urinary free cortisol and other urinary steroid measurements in diagnosis. Q J Med 42:175–204
Gomez MT, Malozowski S, Winterer J, Vamvakopoulos NC, Chrousos GP (1991) Urinary free cortisol values in normal children and adolescents. J Pediatr 118:256–258
Papanicolaou DA, Yanovski JA, Cutler GB Jr, Chrousos GP, Nieman LK (1998) A single midnight serum cortisol measurement distinguishes Cushing’s syndrome from pseudo-Cushing states. J Clin Endocrinol Metab 83:1163–1167
Gorges R, Knappe G, Gerl H, Ventz M, Stahl F (1999) Diagnosis of Cushing’s syndrome: re-evaluation of midnight plasma cortisol vs urinary free cortisol and low-dose dexamethasone suppression test in a large patient group. J Endocrinol Invest 22:241–249
Newell-Price J, Trainer PJ, Perry L, Wass JAH, Grossman AB, Besser GM (1995) A single sleeping midnight cortisol has 100% sensitivity for the diagnosis of Cushing’s syndrome. Clin Endocrinol 43:545–550
Putignano P, Toja P, Dubini A, Pecori Giraldi F, Corsello SM, Cavagnini F (2003) Midnight salivary cortisol versus urinary free and midnight cortisol as screening tests for Cushing’s syndrome. J Clin Endocrinol Metab 88:4153–4157
Jones KL (1990) The Cushing’s syndrome. Pediatr Clin North Am 37:1313–1332
Magiakou MA, Chrousos GP (2002) Cushing’s syndrome in children and adolescents: current diagnostic and therapeutic strategies. J Endocrinol Invest 25:181–194
Streeten DH, Faas FH, Elders MJ, Dalakos TG, Voorhess M (1975) Hypercortisolism in childhood: shortcomings of conventional diagnostic criteria. Pediatrics 56:797–803
Invitti C, Pecori Giraldi F, De Martin M, Cavagnini F (1999) the Study Group of the Italian Society of Endocrinology on the Pathophysiology of the Hypotalamic-Pituitary-Adrenal Axis Diagnosis and management of Cushing’s syndrome: results of an Italian multicentre study. J Clin Endocrinol Metab 84:440–448
Findling JW, Raff H, Aron DC (2004) The low-dose dexamethasone suppression test: a reevaluation in patients with Cushing’s syndrome. J Clin Endocrinol Metab 89:1222–1226
Wood PJ, Barth JH, Freedman DB, Perry L, Sheridan B (1997) Evidence for the low dose dexamethasone suppression test to screen for Cushing’s syndrome—recommendations for a protocol for biochemistry laboratories. Ann Clin Biochem 34:222–229
Yanovski JA, Cutler GB Jr, Chrousos GP, Nieman LK (1993) Corticotropin-releasing hormone stimulation following low-dose dexamethasone administration. JAMA 269:2232–2238
Tsagarakis S, Vasiliou V, Kokkoris P, Stavropoulos G, Thalassinos N (1999) Assessment of cortisol and ACTH responses to the desmopressin test in patients with Cushing’s syndrome and simple obesity. Clin Endocrinol 51:473–477
Moro M, Putignano P, Losa M, Invitti C, Maraschini C, Cavagnini F (2000) The desmopressin test in the differential diagnosis between Cushing’s disease and pseudoCushing states. J Clin Endocrinol Metab 85:3596–3574
Kaye TB, Crapo L (1990) The Cushing’s syndrome: an update on diagnostic tests. Ann Intern Med 112:434–444
Nieman LK, Oldfield EH, Wesley R, Chrousos GP, Loriaux DL, Cutler GB Jr (1993) A simplified morning ovine corticotrophin-releasing hormone stimulation test for the differential diagnosis of adrenocorticotropin-dependent Cushing’s syndrome. J Clin Endocrinol Metab 77:1308–1312
Loriaux DL, Nieman L (1991) Corticotropin-releasing hormone testing in pituitary disease. Endocrinol Metab Clin North Am 20:363–369
Isidori AM, Kaltsas GA, Mohammed S, Morris DG, Jenkins P, Chew SL, Monson JP, Besser GM, Grossman AB (2003) Discriminatory value of the low-dose dexamethasone suppression test in establishing the diagnosis and differential diagnosis of Cushing’s syndrome. J Clin Endocrinol Metab 88:5299–5306
Aron DC, Raff H, Findling JW (1997) Effectiveness versus efficacy: the limited value in clinical practice of high dose dexamethasone suppression testing in the differential diagnosis of adrenocorticotropin-dependent Cushing’s syndrome. J Clin Endocrinol Metab 82:1780–1785
Dichek HL, Nieman LK, Oldfield EH, Pass HI, Malley JD, Cutler Jr GB (1994) A comparison of the standard high dose dexamethasone suppression test and the overnight 8-mg dexamethasone suppression test for the differential diagnosis of adrenocorticotropin-dependent Cushing’s syndrome. J Clin Endocrinol Metab 78:418–422
Reimondo G, Paccotti P, Minetto M, Termine A, Stura G, Bergui M, Angeli A, Terzolo M (2003) The corticotropin-releasing hormone test is the most reliable noninvasive method to differentiate pituitary from ectopic ACTH secretion in Cushing’s syndrome. Clin Endocrinol 58:718–724
Kaltsas GA, Giannulis MG, Newell-Price JD, Dacie JE, Thakkar C, Afshar F, Monson JP, Grossman AB, Besser GM, Trainer PJ (1999) A critical analysis of the value of simultaneous inferior petrosal sinus sampling in Cushing’s disease and the occult ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metab 84:487–492
Colao A, Faggiano A, Pivonello R, Pecori Giraldi F, Cavagnini F, Lombardi G; Study Group of the Italian Endocrinology Society on the pathophysiology of the Hypothalamic-Pituitary-Adrenal Axis (2001) Inferior petrosal sinus sampling in the differential diagnosis of Cushing’s syndrome: results of an Italian multicentre study. Eur J Endocrinol 144:499–507
Swearingen B, Katznelson L, Miller K, Grinspoon S, Waltman A, Dorer DJ, Klibanski A, Biller BM (2004) Diagnostic errors after inferior petrosal sinus sampling. J Clin Endocrinol Metab 89:3752–3763
Pecori Giraldi F, Invitti C, Cavagnini F (2000) Inferior petrosal sinus sampling ten years down the road. J Endocrinol Invest 23:325–327
Ilias I, Chang R, Pacak K, Oldfield EH, Wesley R, Doppman J, Nieman LK (2004) Jugular venous sampling: an alternative to petrosal sinus sampling for the diagnostic evaluation of adrenocorticotropin hormone-dependent Cushing’s syndrome. J Clin Endocrinol Metab 89:3795–3800
Liu C, Lo JC, Dowd CF, Wilson CB, Kunwar S, Aron DC, Tyrrell JB (2004) Cavernous and inferior petrosal sinus sampling in the evaluation of ACTH-dependent Cushing’s syndrome. Clin Endocrinol 61:478–486
Mancini T, Kola B, Mantero F, Boscaro M, Arnaldi G (2004) High cardiovascular risk in patients with Cushing’s syndrome according to 1999 WHO/ISH guidelines. Clin Endocrinol 61:768–777
Dagenais GR, Yi Q, Mann JF, Bosch J, Pogue J, Yusuf S (2005) Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease. Am Heart J 149:54–60
Faggiano A, Pivonello R, Spiezia S, De Martino MC, Filippella M, Di Somma C, Lombardi G, Colao A (2003) Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing’s disease during active disease and 1 year after disease remission. J Clin Endcorinol Metab 88:2527–2533
Melanson KJ, McInnis KJ, Rippe JM, Blackburn G, Wilson PF (2001) Obesity and cardiovascular disease risk: research update. Cardiol Rev 9:202–207
Friedman TC, Mastorakos G, Newman TD, Muller NM, Horton EG, Costello R, Papadopoulos NM, Chrousos GP (1996) Carbohydrate and lipid metabolism in endogenous hypercortisolism: shared features with metabolic syndrome X and NIDDM. Endocr J 43:645–655
Heaney AP, Fernando M, Yong WH, Melmed S (2002) Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med 8:1281–1287
Fatti LM, Bottasso B, Invitti C, Coppola R, Cavagnini F, Mannucci PM (2000) Markers of activation of coagulation and fibrinolysis in patients with Cushing’s syndrome. J Endocrinol Invest 23:145–150
Small M, Lowe GD, Forbes CD, Thomson JA (1983) Thromboembolic complications in Cushing’s syndrome. Clin Endocrinol 19:503–511
Boscaro M, Sonino N, Scarda A, Barzon L, Fallo F, Sartori MT, Patrassi GM, Girolami A (2002) Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing’s syndrome. J Clin Endocrinol Metab 87:3662–3666
Leong GM, Mercado-Asis LB, Reynolds JC, Hill SC, Oldfield EH, Chrousos GP (1996) The effect of Cushing’s disease on bone mineral density, body composition, growth, and puberty: a report of an identical adolescent twin pair. J Clin Endocrinol Metab 81:1905–1911
Faggiano A, Pivonello R, Filippella M, Di Somma C, Orio F Jr, Lombardi G, Colao A (2001) Spine abnormalities and damage in patients cured from Cushing’s disease. Pituitary 4:153–161
Faggiano A, Pivonello R, Melis D, Filippella M, Di Somma C, Peretta M, Lombardi G, Colao A (2003) Nephrolitiasis in Cushing’s disease: prevalence, etiopathogenesis, and modification after disease cure. J Clin Endocrinol Metab 88:2076–2080
Cohen D, Adachi JD (2004) The treatment of glucorticoid-induced osteoporosis. J Steroid Biochem Mol Biol 88:337–349
Orth DN, Kovacs WJ, DeBold CR (1992) The adrenal cortex. In: Wilson JD, Foster DW (eds), Williams textbook of endocrinology. Saunders Co, Philadelphia, pp. 489–619
Sonino N, Fava GA (2001) Psychiatric disorders associated with Cushing’s syndrome. CNS Drugs 15:361–373
Giustina A, Veldhuis JD (1998) Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 19:717–797
Invitti C, Manfrini R, Romanini BM, Cavagnini F (1995) High prevalence of nodular thyroid disease in patients with Cushing’s disease. Clin Endocrinol 43:359–363
Pecori Giraldi F (2004) Sindrome di Cushing e manifestazioni oculari. Boll Ocul 83:1–4
Hammer GD, Tyrrell JB, Lamborn KR, Applebury CB, Hannegan ET, Bell S, Rahl R, Lu A, Wilson CB (2004) Transsphenoidal microsurgery for Cushing’s disease: initial outcome and long-term results. J Clin Endocrinol Metab 89:6348–6357
Lüdecke DK, Flitsch J, Knappe UJ, Saeger W (2001) Cushing’s disease: a surgical review. J Neurooncol 54:151–166
Bochicchio D, Losa M, Buchfelder M (1995) Factors influencing the immediate and late outcome of Cushing’s disease treated by transsphenoidal surgery: a retrospective study by the European Cushing’s Disease Survey Group. J Clin Endocrinol Metab 80:3114–3120
Trainer PJ, Lawrie HS, Verhelst J, Howlett TA, Lowe DG, Grossman AB, Savage MO, Afshar F, Besser GM (1993) Transsphenoidal resection in Cushing’s disease: undetectable serum cortisol as the definition of successful treatment. Clin Endocrinol 38:73–78
Ram Z, Nieman LK, Cutler GB Jr, Chrousos GP, Doppman JL, Oldfield EH (1994) Early repeat surgery for persistent Cushing’s disease. J Neurosurg 80:37–45
Becker G, Kocher M, Kortmann RD, Paulsen F, Jeremic B, Muller RP, Bamberg M (2002) Radiation therapy in the multimodal treatment approach of pituitary adenoma. Strahlenther Onkol 178:173–186
Minniti G, Traish D, Ashler S, Gonsalves A, Brada M (2005) Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: update after additional 10 years. J Clin Endocrinol Metab 90:800–804
Mahmoud-Ashmed AS, Suh JH (2002) Radiation therapy for Cushing’s disease: a review. Pituitary 5:175–180
Sharpe GF, Kendall-Taylor P, Prescott RW, Ross WM, Davison C, Watson MJ, Cook DB (1985) Pituitary function following megavoltage therapy for Cushing’s disease: long term follow up. Clin Endocrinol 22:169–177
Estrada J, Boronat M, Mielgo M, Magallon R, Millan I, Diez S, Lucas T, Barcelo B (1997) The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing’s disease. N Engl J Med 336:172–177
Jennings AS, Liddle GW, Orth DN (1977) Results of treating childhood Cushing’s disease with pituitary irradiation. N Engl J Med 297:957–962
Sheehan JM, Vance ML, Sheehan JP, Ellegala DB, Laws ER Jr (2000) Radiosurgery for Cushing’s disease after failed trassphenoidal surgery. J Neurosurg 93:738–742
Hoybye C, Grenback E, Rahn T, Degerblad M, Thoren M, Hulting AL (2001) Adrenocorticotropic hormone-producing pituitary tumours: 12- to 22-year follow-up after treatment with stereotactic radiosurgery. Neurosurgery 49:284–291
Mitsumori M, Shrieve DC, Alexander E 3rd, Kaiser UB, Richardson GE, Black PM, Loeffler JS (1998) Initial clinical results of LINAC-based stereotactic radiosurgery and stereotactic radiotherapy for pituitary adenomas. Int J Radiat Oncol Biol Phys 42:573–580
Molinatti GM, Limone P, Porta M (1995) Treatment of Cushing’s disease by interstitial pituitary irradiation: short- and long-term follow-up. Panminerva Med 37:1–7
Sandler LM, Richards NT, Carr DH, Mashiter K, Joplin GF (1987) Long term follow-up of patients with Cushing’s disease treated by interstitial irradiation. J Clin Endocrinol Metab 65:441–447
Cavagnini F, Pecori Giraldi F (2006) In: DeGroot LJ, Jameson JL (eds), Adrenal causes of hypercortisolism. Endocrinology. Elsevier Saunders, Philadelphia, pp 2353–2386
Imai T, Funahashi H, Tanaka Y, Tobinaga J, Wada M, Morita-Matsuyama T, Ohiso Y, Takagi H (1996) Adrenalectomy for treatment of Cushing’s syndrome: results in 122 patients and long-term follow-up studies. World J Surg 20:781–786
Welbourn RB (1985) Survival and causes of death after adrenalectomy for Cushing’s disease. Surgery 97:16–20
Nieman LK (2002) Medical therapy of Cushing’s disease. Pituitary 5:77–82
Morris D, Grossman A (2002) The medical management of Cushing’s syndrome. Ann N Y Acad Sci 970:119–133
Sonino N, Boscaro M (1999) Medical therapy for Cushing’s disease. Endocrinol Metab Clin North Am 28:211–222
Schulte HM, Benker G, Reinwein D, Sippell WG, Allolio B (1990) Infusion of low dose etomidate: correction of hypercortisolemia in patients with Cushing’s syndrome and dose-response relationship in normal subjects. J Clin Endocrinol Metab 70:1426–1430
Kawai S, Ichikawa Y, Kaburaki J, Yoshida T (1999) 18 years mitotane therapy for intractable Cushing’s disease. Lancet 354:951
Schteingart DE, Tsao HS, Taylor CI, McKenzie A, Victoria R, Therrien BA (1980) Sustained remission of Cushing’s disease with mitotane and pituitary irradiation. Ann Intern Med 92:613–619
Chu JW, Matthias DF, Belanoff J, Schatzberg A, Hoffman AR, Feldman D (2001) Successful long-term treatment of refractory Cushing’s disease with high-dose mifepristone (RU486). J Clin Endocrinol Metab 86:3568–3573
Kelly PA, Samandouras G, Grossman AB, Afshar F, Besser GM, Jenkins PJ (2002) Neurosurgical treatment of Nelson’s syndrome. J Clin Endocrinol Metab 87:5465–5469
Dornhorst A, Jenkins JS, Lamberts SW, Abraham RR, Wynn V, Bechford U, Gillham B, Jones MT (1983) The evaluation of sodium valproate in the treatment of Nelson’s syndrome. J Clin Endocrinol Metab 56:985–991
Pivonello R, Faggiano A, Di Salle F, Filippella M, Lombardi G, Colao A (1999) Complete remission of Nelson’s syndrome after 1-year treatment with cabergoline. J Endocrinol Invest 22:860–865
Casulari LA, Naves LA, Mello PA, Pereira Neto A, Papadia C (2004) Nelson’s syndrome: complete remission with cabergoline but not with bromocriptine or cyproheptadine treatment. Horm Res 62:300–305
Petrini L. Gasperi M, Pilosu R, Marcello A, Martino E (1994) Long-term treatment of Nelson’s syndrome by octreotide: a case report. J Endocrinol Invest 17:135–139
McCance DR, Besser M, Atkinson AB (1996) Assessment of cure after transsphenoidal surgery for Cushing’s disease. Clin Endocrinol 44:1–6
Colombo P, Dall’Asta C, Barbetta L, Re T, Passini E, Faglia G, Ambrosi B (2000) Usefulness of the desmopressin test in the postoperative evaluation of patients with Cushing’s disease. Eur J Endocrinol 143:227–234
Vallette-Kasic S, Dufour H, Mugnier M, Trouillas J, Valdes-Socin H, Caron P, Morange S, Girard N, Grisoli F, Jaquet P, Brue T (2000) Markers of tumor invasion are major predictive factors for the long-term outcome of corticotroph microadenomas treated by transsphenoidal adenomectomy. Eur J Endocrinol 143:761–768
Davies JH, Storr HL, Davies K, Monson JP, Besser GM, Afshar F, Plowman PN, Grossman AB, Savage MO (2005) Final adult height and body mass index after cure of paediatric Cushing’s disease. Clin Endocrinol 62:466–472
Kemink SA, Grotenhuis JA, De Vries J, Pieters GF, Hermus AR, Smals AG (2001) Management of Nelson’s syndrome: observations in fifteen patients. Clin Endocrinol 54:45–52
Colao A, Pivonello R, Spiezia S, Faggiano A, Ferone D, Filippella M, Marzullo P, Cerbone G, Siciliani M, Lombardi G (1999) Persistence of increased cardiovascular risk in patients with Cushing’s disease after five years of successful cure. J Clin Endocrinol Metab 84:2664–2672
Manning PJ, Evans MC, Reid IR (1992) Normal bone density following cure of Cushing’s syndrome. Clin Endocrinol 36:229–234
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
De Martin, M., Giraldi, F.P. & Cavagnini, F. Cushing’s disease. Pituitary 9, 279–287 (2006). https://doi.org/10.1007/s11102-006-0407-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11102-006-0407-6